Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2639MR)

This product GTTS-WQ2639MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001290023.2; NM_001258214.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3594; 3595
UniProt ID P42701; Q99665
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2639MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15348MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ5479MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ14227MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ9832MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ8005MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ9710MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ7088MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ15345MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW